Viewing Study NCT03013296



Ignite Creation Date: 2024-05-06 @ 9:34 AM
Last Modification Date: 2024-10-26 @ 12:16 PM
Study NCT ID: NCT03013296
Status: COMPLETED
Last Update Posted: 2019-06-04
First Post: 2017-01-03

Brief Title: Delinieation of GIPs Effects During a Meal in Humans Using GIP Receptor Antagonisation GA-4
Sponsor: University Hospital Gentofte Copenhagen
Organization: University Hospital Gentofte Copenhagen

Study Overview

Official Title: Delinieation of GIPs Effects During a Meal in Humans Using GIP Receptor Antagonisation GA-4
Status: COMPLETED
Status Verified Date: 2019-06
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Delinieation of GIPs effects during a meal in humans using GIP receptor antagonisation
Detailed Description: Aim To evaluate the role of GIPR signalling in postprandial physiology including lipid bone and glucose homeostasis using a naturally occurring GIP fragment which antagonises the GIPR

Twelve healthy men age 18-70 years BMI 19-27 kgm2 with normal kidney and liver parameters and haemoglobin levels and no first-degree relatives with type 2 diabetes will be included in a randomised double-blinded placebo-controlled cross-over study Study consists of four study days with concomitant infusions of A GIP-A B GLP-1 receptor antagonist Exendin9-39 C GIP-A Exendin9-39 or D saline placebo

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None